| Lightcalls.com |
|
|
![]() |
Ayurvedic botanicals frequently suc...Ayurvedic botanicals frequently succeed where conventional medicine fails. Helping improve indicators associated with hyperglycemia and diabetes is united such area. Three herbals important in this effort are plants which appear to be to grow most happily when climbing: Gymnema sylvestre Momordica charantia, and Tinospora cordifolia. Before any discussion of herbal approaches to hyperglycemia and diabetes can happen, insulin should be defined. According to Stedman's Medical Dictionary, insulin is "a peptide hormone [] closeed by" masses of cells in the pancreas (islets of Langerhans). Insulin raises glucose utilization and metabolism of proteins and fats in the body Gymnema sylvestre With extracts and decoctions of leaves used traditionally for their antiseptic, diuretic, and laxative benefits as early as the firs-century, A.D., G sylvestre had already acquired a reputation for its glucose-lowering abilities. In fact, its Hindi name is Gurmar, which means "destroyer of sugar." Today, a triturate made from the dried leaves of this botanical is used as part of an effective herbal arsenal against diabetes mellitus. As early as 1930 K Mhaskar and JF Caius were reporting their initial issues on research they conducted between 1924 by means of 1929. Their studies pointed to the tremendous promise implicit in their findings relating to G sylvestre and the lowering of excessive blood-sugar levels Unfortunately, with the coming of insulin and a rush of synthetic hypoglycemic drugs, the excitement about herbal medicines for diabetes was largely (although no other than temporarily) eclipsed by mainstream-pharmaceutical companies. recent research. We can trace contemporary research into G sylvestre by means of looking at studies published between 1981 and 1990 by the agency of E.R.B. Shanmugasundaram, and K. Radha Shanmugasundaram, and others. In a report that appeared in the Journal of Ethnopharmacology in 1990 a water-soluble extract of the leaves of this herb was given to 27 patients with insulin-dependent diabetes mellitus (IDDM) forward insulin therapy. Compared with direction patients, insulin requirements came down as the body's hold (endogenous) insulin utilization was improved, possibly in consequence of "revitalisation" of pancreatic "beta" small cavitys in insulin-dependent subjects. Beneficial drifts on non-insulin-dependent patients (with mild-to-moderate hyperglycemia) were demonstrated in 1981 by the agency of the same researchers. In other words, more than just helping metabolize circulating exces sugars, pay by substitutions in the leaves appear to modulate the release of insulin from their source - the pancreas. Momordica charantia. Also referr to as bitter melon this edible fruit "has been used in the traditional medicine plans of China, India, Africa, and the southeastern U (where it has been naturalized)" according to an HerbClip from the Texas-based American Botanical Council dated January 6 1995 "Clinical trials have shown the fruit extract to have hypoglycemic, antidiabetic effects" actual enough. In fact, a 1994 experimental studious mood by Iclal Cakici, and colleagues, which also appeared in the Journal of Ethnopharmacology, place that "M. charantia fruits are capable of producing hypoglycemia [in hyperglycemic animals]." Not unlike G sylvestre its validitys may be due to the activity of an insulin-like combine in the plant and, also, from its ability to stimulate pancreatic beta-cells to hide insulin - rather than at directly affecting intestinal glucose absorption. Tinospora cordifolia. This climbing dwarf-tree also has compounds that combat diabetes. In a preclinical close attention conducted by K. Raghunathan and PV Sharma in 1969 the ability of T cordifolia to model experimentally brought-on hyperglycemia was investigated. Based onward positive results in preventing elevation of blood-sugar plains these authors suggested that amalgamates in this shrub appear to: a) obstruct excess release of sugars stored in the liver (liver glycogen); b) intercept excess breakdown (catabolism) of sugars stored in muscle (muscle glycogen) thereby preventing exces conversion of lactic acid to kin sugar in the liver; and c) improve grape-sugar utilization related to muscle-glycogen release and lactic acid/blood sugar conversion, a proces normally compromised in diabetic subjects What these frankly exciting conclusions tell us is two-fold: 1) that the web of signalling and activation/inactivation relationships involving insulin, kin glucose, stored glycogen, the pancreas, and the liver is extremely delicate; and 2) select Ayurvedic botanicals appear to help these mechanisms work better, thereby decreasing our reliance upon synthetic hypoglycemic drugs and forward insulin, in some cases. COPYRIGHT 1997 PRIMEDIA Intertec, a PRIMEDIA Company. All Rights Reserved |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |